Artigo Acesso aberto Revisado por pares

ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non–Small Cell Lung Cancer (NSCLC)

2017; Elsevier BV; Volume: 12; Issue: 9 Linguagem: Inglês

10.1016/j.jtho.2017.07.005

ISSN

1556-1380

Autores

Byoung Chul Cho, Dong‐Wan Kim, Alessandra Bearz, Scott A. Laurie, Mark J. McKeage, Gloria Borra, Keunchil Park, Sang-We Kim, Marwan Ghosn, Andrea Ardizzoni, Evaristo Maiello, Alastair Greystoke, Richard Yu, Karen A. Osborne, Wen Gu, Jeffrey W. Scott, Vanessa Q. Passos, Yvonne Lau, Anna Wrona,

Tópico(s)

Gastric Cancer Management and Outcomes

Referência(s)